Given the heterogeneity of studies of PCSK9 inhibitors in CKD populations, a specific meta-analysis summarizing data from all available randomized controlled trials and high-quality observational studies would be extremely valuable. The gene discussed is PCSK9; the disease is chronic kidney disease.